Race Oncology (AX:RAC) is developing bisantrene, which had been the subject of over 40 clinical trials in the 1980s and 1990s as part of Lederle’s search for a safer anthracycline chemotherapy.
Despite positive responses in a variety of cancers, especially AML (it was even approved for the treatment of AML in France, but never commercialised), development stopped after Lederle was sold to Wyeth and then Wyeth to Pfizer (NYSE:PFE). Race will be developing bisantrene initially for relapsed/refractory AML and expects to start a pivotal trial for approval in the US around the end of 2018.